Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone
J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone
J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone
Submitted by
admin
on September 13, 2016 - 10:06am
Source:
Endpoints
News Tags:
JNJ
GSK
rheumatoid arthritis
sirukumab
FDA
Europe
Headline:
J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone
Do Not Allow Advertisers to Use My Personal information
